目的:评价拉科沙胺(LCM)单药治疗在妊娠和哺乳期间的安全性。
方法:在大学癫痫诊所接受LCM单药治疗的患者在怀孕期间进行了前瞻性随访,delivery,和母乳喂养。癫痫发作频率的数据,LCM用量,怀孕过程,分娩和母乳喂养,出生结果,先天性畸形,收集新生儿的发育。
结果:报告了用LCM单药治疗的3例难治性局灶性癫痫患者中的4例妊娠。这些怀孕之一在妊娠的第七周以流产告终。受孕时的平均每日LCM剂量为300mg。在整个妊娠和母乳喂养期间继续用LCM治疗。在两次怀孕中,LCM的剂量增加:在一次癫痫发作复发后,在另一种情况下,作为避免癫痫发作频率增加的预防措施。在两种情况下,怀孕期间癫痫发作频率保持稳定。所有分娩都是通过剖腹产进行的,出生时的平均胎龄为37.6周。所有新生儿的阿普加评分都是10分,没有发现先天性畸形。在12个月大的时候,达到了正常的发展里程碑。婴儿进行母乳喂养,没有任何并发症。
结论:该病例系列增加了越来越多的证据,表明LCM单一疗法在整个妊娠和母乳喂养期间的相对安全性。
OBJECTIVE: To evaluate the safety of lacosamide (LCM) monotherapy during pregnancy and breastfeeding.
METHODS: Patients taking LCM monotherapy treated at the university epilepsy clinic were prospectively followed up during pregnancy, delivery, and breastfeeding. Data on seizure frequency, LCM dosage, pregnancy course, delivery and breastfeeding, birth outcome, congenital malformation, and development of newborns was collected.
RESULTS: Four pregnancies in three patients with refractory focal epilepsy treated with LCM monotherapy were reported. One of these pregnancies ended in a miscarriage during the seventh week of gestation. The average daily LCM dose at the time of conception was 300 mg. Treatment with LCM was continued throughout pregnancy and breastfeeding. The dose of LCM was increased in two pregnancies: in one
case following a seizure relapse, and in the other
case as a preventive measure to avoid an increase in seizure frequency. Seizure frequency remained stable during pregnancy in two cases. All deliveries were carried out via caesarean section, with an average gestational age at birth of 37.6 weeks. The Apgar score was 10 in all newborns, and no congenital
malformations were detected. At the age of 12 months, normal developmental milestones were reached. Infants were breastfed without any complications.
CONCLUSIONS: This
case series adds to a growing body of evidence suggesting the relative safety of LCM monotherapy throughout pregnancy and breastfeeding.